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Abstract
Several European countries have established criteria for prioritising initiation of treatment in
patients infected with the hepatitis C virus (HCV) by grouping patients according to clinical
characteristics. Based on neural network techniques, our objective was to identify those fac-
tors for HIV/HCV co-infected patients (to which clinicians have given careful consideration
before treatment uptake) that have not being included among the prioritisation criteria. This
study was based on the Spanish HERACLES cohort (NCT02511496) (April-September
2015, 2940 patients) and involved application of different neural network models with differ-
ent basis functions (product-unit, sigmoid unit and radial basis function neural networks)
for automatic classification of patients for treatment. An evolutionary algorithm was used to
determine the architecture and estimate the coefficients of the model. This machine learning
methodology found that radial basis neural networks provided a very simple model in terms
of the number of patient characteristics to be considered by the classifier (in this case, six),
returning a good overall classification accuracy of 0.767 and a minimum sensitivity (for the
classification of the minority class, untreated patients) of 0.550. Finally, the area under the
ROC curve was 0.802, which proved to be exceptional. The parsimony of the model makes
it especially attractive, using just eight connections. The independent variable “recent
PWID” is compulsory due to its importance. The simplicity of the model means that it is
possible to analyse the relationship between patient characteristics and the probability of
belonging to the treated group.
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Introduction
Chronic hepatitis C virus infection (HCV) is a major cause of cirrhosis, liver transplantation
and liver-related deaths worldwide [1]. Since HCV and HIV share routes of transmission, it is
common to find that HIV-infected patients are also infected with HCV [2], which carries the
worst prognosis in these patients due to its faster progression and comorbidities [3, 4]. Hence,
treatment uptake in this population is mandatory. In the last few years, direct-acting antiviral
drugs (DAAs) with high cure rates (defined as sustained virological response) have become
available for the treatment of HCV infection [5]. Even though there is a strong recommenda-
tion for universal treatment of this disease [6, 7], due to the high numbers of patients waiting
for treatment, the scientific societies and health authorities have established various prioritisa-
tion criteria for initiating therapy based on achieving maximum survival and clinical benefits
for the patient. The implementation of this strategy and the commitment of clinicians to these
recommendations have not so far been evaluated. Identifying patient-related variables that
could limit treatment uptake in HIV/HCV co-infected patients, even when the prioritisation
criteria for treatment are fulfilled, is an important issue.
Multilayer perceptron (MLP) artificial neural networks (ANN) [8] have been widely used
in this field to model nonlinear functions for classification. Several studies have demon-
strated that the methodology is appropriate in this context: Wang et al. [9] successfully
applied the ANN methodology to predict virological response to therapy from HIV geno-
type. Resino et al. [10] studied an ANN trained to predict significant fibrosis among HIV/
HCV co-infected patients using clinical data derived from peripheral blood, concluding that
the ANN technique was a helpful tool in clinical practice for guiding therapeutic decisions
in HIV/HCV co-infected patients. Lamer et al. [11] demonstrated the use of ANNs trained
using evolutionary computation to predict R5, X4 and R5X4 HIV-1 co-receptor usage; their
results indicated the identification of R5X4 viruses with a predictive accuracy of 75.5%. Prad-
han and Sahu [12] presented a new MLP network that used seven different patient character-
istics as inputs (age, sex, weight, HB, CD3, CD8 and TB) to classify the HIV/AIDS-infected
and non-infected status of individuals. In short, the literature shows that this methodology
has already been successfully applied in the field of HIV prediction and obtained good per-
formance [13].
Feedforward neural networks, in which the information moves in a forward direction, are
the commonest and simplest type of ANN [14]. Our study proposal included three ANNs that
differed according to the basis function used: product unit neural network (PUNN) [15], sig-
moid unit neural network (SUNN) [8], and finally, the radial basis function neural network
(RBFNN) [16]. All these methods have been widely used in biomedicine since 1990 and are
still in use today: see [17–19] for RBFNN, [20–22] for MLP or SUNN and [23, 24] for PUNN.
Finally, all these ANN models have been proven to be universal approximators [8]. Moreover,
there are various applications of evolutionary neural network models in biomedicine. Vukice-
vic et al. presented an evolutionary algorithm to train ANNs to predict the outcome of surgery
for choledocholithiasis [25]. Cruz-Ramı´rez et al. used a multi-objective evolutionary algorithm
to train RBFNNs to predict patient survival after liver transplantation [26]. Dorado-Moreno
et al. two approaches in combination, a cost-sensitive evolutionary ordinal ANN and an ordi-
nal over-sampling technique, to tackle the same problem [27].
The main objective of this study was to develop an empirical and parsimonious classifica-
tion model to treat/not treat HIV/HCV-infected patients with antiretrovirals, trying to
maximise overall accuracy, to achieve a good classification for the minority class (untreated
patients) and to obtain a good performance in all the possible classification thresholds. Spain,
which provides universal and free health care access, established different criteria in April
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2015 for the initiation and prioritization of HCV treatment, which are known as the Spanish
National Strategy for HCV treatment. This strategy recognised different scenarios based on
the disease severity (such as liver fibrosis stage and extrahepatic manifestations), comorbidi-
ties, epidemiology (such as risk of transmission population or women wishing to be pregnant),
etc. [10]. The application of this strategy has had an evident beneficial impact on short-term
treatment uptake [11]. Nevertheless, clinical, epidemiological and geographic factors associ-
ated with lower treatment odds have not been evaluated. Understanding patient factors associ-
ated with being untreated for HCV would help in supporting extra efforts in those patients in
order to eliminate HCV in the coming years. In this sense, a large number of experimental
tests were carried out with several basis functions associated with different neural network
types. The secondary objective was to find the simplest possible model able to analyse the influ-
ence of patient characteristics on the probability of belonging to the treated group.
Materials and methods
Resource and setting
The patients considered were part of the HERACLES cohort. This prospective observational
cohort included HIV-infected patients with active chronic HCV infection in follow-up at 19
reference centres in Andalusia (clinicaltrials.gov identification: NCT02511496). Active chronic
HCV infection was defined as detectable HCV RNA in serum or plasma for 6 months or
more. The cohort was set up in March 2015 with the main objective of evaluating the HCV
treatment rate among included patients. The population included in this cohort represented
99.9% of HIV-infected individuals in follow-up in Andalusia. Patients included in the cohort
were followed-up every three months according to clinical practice. The time period of this
analysis was 2 years.
Criteria for initiation of HCV treatment
Treatment was initiated in each individual in accordance with the prioritisation criteria estab-
lished in Spain’s national strategic plan for HCV treatment. This strategic plan recognises
different scenarios and criteria based on disease severity (such as liver fibrosis stage and extra-
hepatic manifestations), comorbidities, and epidemiology (such as population transmission
risk or women hoping to become pregnant). Nevertheless, the final decision to initiate HCV
therapy was taken by the clinician in charge. Patients who initiated therapy were classified as
those who i) met the criteria, or ii) did not meet the criteria, depending on whether they did or
did not satisfy the criteria for HCV treatment set out in the strategic plan.
Variable collection and definition
The following variables were included and recorded: age, gender, route of transmission of HIV
and HCV, HCV genotype, liver fibrosis stage, history of HCV therapy (treatment-naïve, Peg-
IFN/RBV-treated patients, DAAs + Peg-IFN/RBV-treated patients), comorbidities, presence
of active major psychiatric disorders, recent drug abuse, opioid substitution therapy (OST)
use, convictions, and adherence to clinical visits. People who inject drugs (PWIDs) were cate-
gorised as lifetime PWID (people who had injected drugs at some point but there is no current
OST use or drug abuse), OST-PWID (OST use, but no drug use in the last 3 months) and
recent PWID (evidence of drug consumption in the previous 3 months). Liver transient elasto-
graphy by FibroScan (FibroScan; Echosens, Paris) was used for liver stiffness measurements
(LSM) and grading and staging of liver fibrosis. Liver fibrosis stages were defined as follows: i)
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F0 − F1� LSM< 7.2 kPa; ii) F2� 7.2� LSM� 8.9 kPa; iii) F3� 9� LSM� 14.5 kPa; and
iv) F4� LSM� 14.6 kPa.
ANN models
The problem considered in this study was to predict the need for treatment of patients co-
infected with HIV/HCV. To estimate the model, a training set of NT samples was required,
ðxi; yiÞ; i ¼ 1 . . .NT; xi 2 R
d; yi 2 f0; 1g, where d is the number of inputs of the model and yi
represents a binary variable coding the need of treatment (yi = 1) or the absence of this need
(yi = 0). Nonlinear functions were applied to solve the problem, specifically the following artifi-
cial neural networks (ANN): product unit neural networks (PUNN) [28], sigmoid unit neural
network (SUNN) [29], and radial basis function neural network (RBFNN) [16].
The differences between the proposed basis functions are as follows: PUNN models are
highly versatile for implementing high-order functions, retaining the properties of a universal
approximator while using only a small number of neurons with multiplicative rather than
additive units [30]. SUNN models use sigmoid transfer functions for hidden layer nodes. This
is the most widely used type of neural network because of its ability to approximate any contin-
uous function with sufficient accuracy. Finally, RBFNN models approximate underlying func-
tions by using a linear combination of semiparametric nonlinear functions, such as Gaussians.
This kind of function has two main advantages: the simplicity of its structure and the speed of
the learning algorithms it employs. None of these models requires a large number of neurons
to solve certain problems [31], which makes them reasonable choices to apply to this problem.
To train the ANN models, an evolutionary algorithm inspired on that developed by Angel-
ine et al. [32] and extended afterwards [28, 33] was used, with the purpose of estimating the
parameters and the architecture of the ANNs. The use of evolutionary learning for designing
these models dates back to the 1990s (see [34] for an initial review and [35] for a more recent
one). Much work has been done during this period, leaving many different approaches and
working models [36–39].
In this way, evolutionary computation has been used to learn both the architecture and the
connections and weights of the neural network [28]. The main advantage of evolutionary com-
putation is that it performs a global exploration of the search space to avoid becoming trapped
in local minima, which is often the case with local search procedures.
Population and characteristics
This study was based on the Spanish HERACLES cohort (NCT02511496) (April-September
2015), which included 2940 HIV/HCV co-infected patients with the characteristics shown in
Table 1.
At the end of follow-up, of those 1952 patients who received therapy against HCV chronic
infection, 1348 (69.0%) met the criteria of Spain’s strategic plan for HCV treatment, and 604
did not (31.0%). And of the 988 patients who did not receive therapy, 305 (30.8%) met the cri-
teria for receiving therapy according to the strategic plan for HCV treatment, and 683 did not
(69.2%).
At the end of follow-up, of the 1952 patients who received treatment for HCV chronic
infection, 1348 (69.0%) fulfilled the criteria for HCV treatment laid down in Spain’s strategic
plan and 604 did not (31.0%). Of the 988 patients who did not receive treatment, 305 (30.8%)
met the criteria for receiving therapy according to the strategic plan for HCV treatment and
683 did not (69.2%).
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Experimental design
Before training the model, the input variables were scaled in the range [1, 2] for PUNN models
to prevent input values close to zero, which produces large values in the case of negative expo-
nents. The upper boundary was chosen to avoid substantial changes on the outputs when
weights and exponents are high. For SUNN models, the inputs were scaled in the range [0.1,
0.9] to avoid saturation in the sigmoid basis function when weights are very high. Finally, in
the case of the RBFNN models, the inputs were scaled in the range [−1, 1] since these functions
are symmetric on the origin. The following Equation shows an example of the scale of input Xi
for SUNN models:
X�i ¼
Xi   min ðXiÞ
max ðXiÞ   min ðXiÞ
ð0:9   0:1Þ þ 0:1: ð1Þ
For the experimental design, the holdout procedure was used: the training set size was 75%
of the whole dataset, while the remaining 25% was used for the generalisation set.
The performance of each model was evaluated according to accuracy (also known as Cor-
rect Classification Rate, CCR), minimum sensitivity (MS), area under the ROC curve (AUC),
Table 1. Characteristics of the Spanish HERACLES cohort (NCT02511496).
Description Variable Values Occurrences Percentage
Met the Spanish criteria plan X1 No 1287 43.77%
Yes 1653 56.22%
PWID Category X2 Lifetime PWID 2169 73.78%
X3 OST PWID 339 11.53%
X4 Recent PWID 47 1.60%
X5 Never PWID 385 13.10%
Presented major psychiatric disorders X6 No 2886 98.16%
Yes 54 1.84%
Been in jail X7 No 2823 96.02%
Yes 117 3.98%
Previous treatment experience X8 Naïve to therapy 2053 69.83%
X9 With Peg-IFN/RBV 725 24.66%
X10 With DAAs/Peg-IFN/RBV 162 5.51%
Liver fibrosis X11 Stage F0-F1 898 30.54%
Stage F2 475 16.16%
Stage F3 787 26.77%
Stage F4 780 26.53%
Gender X12 Female 491 16.70%
Male 2449 83.30%
Age X13 Continuous variable min 18
max 76
mean 48.95
HCV genotype X14 Genotype 1 1741 59.22%
X15 Genotype 2 27 0.92%
X16 Genotype 3 484 16.46%
X17 Genotype 4 688 23.40%
Received therapy for HCV infection y No 988 33.60%
Yes 1952 66.40%
https://doi.org/10.1371/journal.pone.0227188.t001
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and number of connections (#conn), the latter being used to determine the parsimony of the
model. The CCR and MS were obtained from the confusion matrix, CM:
CM ¼ nij;
XJ
i;j
nij ¼ N
( )
; ð2Þ
where J is the number of classes (two in this case), N is the number of training or testing pat-
terns, and nij represents the number of times the patterns are predicted to belong to class j
when they really belong to class i. The first two measures of classifier performance, CCR and
MS, were calculated from the confusion matrix, while the AUC was obtained from the pre-
dicted probabilities:
• The CCR measure is given by the expression CCR ¼ 1N
PJ
j¼1 njj, where njj is the number of
patterns from the j-th class that are correctly classified in that class. In other words, CCR
is the sum of the elements belonging to the diagonal of the confusion matrix divided by N.
CCR is a value between 0 and 1, where 0 means that none of the instances have been classi-
fied correctly, while 1 involves that there were no errors for any instance.
• MS is the minimum value of the sensitivities for each class [40], which is defined as MS =
min(S1, S2), where Sj is the sensitivity for class j, i.e. Sj ¼ 100
nj
Nj
, nj being the number of
instances correctly classified for class j and Nj being the total number of instances for class j.
MS is a value between 0 and 1, where 0 means that one class was completely misclassified,
while 1 means there were no errors for any class.
• AUC is the area under the ROC curve, which is a common technique to compare the perfor-
mance of two or more binary classifiers and is especially common in medical decision mak-
ing [41]. The ROC curve is a graphical plot that illustrates the relative trade-offs between the
costs and benefits of a classifier, enabling visual comparison of different classifiers. The AUC
is used to make numerical comparisons. AUC is a value between 0 and 1, where 0 means
that all the predictions made were incorrect, while 1 means that all instances were correctly
classified.
The evolutionary algorithm was run using the following parameters. In the case of product
units, the weights between the input layer and hidden layer were initialised in the range [−1, 1]
and those between the hidden layer and output layer in the range [−5, 5]. In the case of the sig-
moidal units and radial basis functions, both weights were initialised in the range [−5, 5]. The
population size was 2940, randomly split into two datasets: 2193 instances were used for train-
ing and the remaining 747 instances were used for the generalisation set. Since the evolution-
ary algorithm is a stochastic method, the algorithm was repeated 30 times for 600 generations,
with a different random seed for each run. In addition, the number of nodes and connections
to be created or deleted fell within the range [1, 2]. Finally, the minimum number of hidden
nodes, the maximum number of hidden nodes in the initialisation phase and the maximum
number of hidden nodes in the whole evolutionary process were set at 1, 2, and 4, respectively.
All these values were selected following a 5-fold cross-validation on the training set, and the
remaining values were obtained from Herva´s-Martı´nez et al. [42].
Results
The performance of each of the proposed techniques was measured according to test CCR, test
MS, test AUC #conn. The performance of the best model, including the set of independent vari-
ables finally considered for the model, is shown in Table 2. Based on these results and focusing
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on the highest AUC values obtained, the RBFNN model stands out with an AUC of 0.802, indi-
cating that it is good at separating treated from untreated patients. Apart from the AUC, the
RBFNN also returned competitive values for the other performance metrics, with scores of 0.550
for MS, indicating that the minority class was correctly classified, and 0.767 for the CCR, which is
the global performance of the classifier. It should be borne in mind however that the CCR is not
advisable for imbalanced datasets (in our case, 1952 treated and 988 untreated patients). Finally,
the main advantage of this technique is the low number of connections used, 8.
The PUNN technique also achieved a good performance, yielding a score of 0.801 for the
AUC and 0.579 for MS, but using a higher number of connections, 11. The last technique,
SUNN, gave the worst AUC and MS performance and used the highest number of connec-
tions, 19.
In order to assess the quality of the ANN models, a comparison against Support Vector
Machines (SVMs) [43] was carried out. In this way, a 5-fold cross-validation method optimis-
ing the AUC measure, was run to select the best value for the penalty of the error (C) and for
the RBF kernel coefficient (γ), both chosen within the range {10−4, 10−3, . . .102}. The results
obtained were 0.755 in terms of CCR and 0.716 for AUC, being clearly worse than the ones
obtained by the models in Table 2, whereas in terms of MS, it led to 0.603, slightly better than
the MS obtained by the ANN models.
Attention is drawn to the importance of input variable X4 (“recent PWIDs”) among the
classifiers used, since it was included in all the best models and its non-inclusion in the
RBFNN model (called RBFNN2) reduced the mean AUC from 0.795 ± 0.005 to 0.483 ± 0.028
and the mean MS from 0.550 ± 0.008 to 0.014 ± 0.019, making it a trivial classifier that classifies
most instances in one class.
Taking into account the mean values obtained, it may be concluded that the best technique
is the RBFNN, since it achieved the best results for AUC, #conn and CCR and a reasonably
good performance for MS. It is also worth noting that the use of just six input variables makes
the model easy to interpret, easy to implement and requires little training time, while the rest
of the techniques need more than 6 input variables.
Table 2. Values of test CCR, MS and AUC, together with #conn, using PUNN, SUNN and RBFNN. The independent variables selected for the best model are also
shown. The best result is highlighted in bold face; the second best result is shown in italics.
Mean±SD
Model CCR MS AUC #conn
PUNN (17-1,2,4-1) 0.767 ± 0.004 0.559 ± 0.012 0.794 ± 0.003 9.46 ± 1.57
SUNN (17-1,2,4-1) 0.762 ± 0.006 0.563 ± 0.014 0.793 ± 0.002 14.10 ± 1.63
RBFNN (17-1,2,4-1) 0.768 ± 0.004 0.550 ± 0.008 0.795 ± 0.005 7.36 ± 1.83
RBFNN2 (16-1,2,4-1) 0.456 ± 0.127 0.014 ± 0.019 0.483 ± 0.028 7.33 ± 2.17
Best Model
Model CCR MS AUC #conn
PUNN (17-1,2,4-1) 0.771 0.579 0.801 11
SUNN (17-1,2,4-1) 0.771 0.545 0.799 19
RBFNN (17-1,2,4-1) 0.767 0.550 0.802 8
RBFNN2 (16-1,2,4-1) 0.514 0.000 0.573 9
Independent variables considered:
PUNN (17-1,2,4-1) X2, X4, X5, X9, X11, X13, X14, X17
SUNN (17-1,2,4-1) X2, X3, X4, X6, X7, X9, X10, X11, X13
RBFNN (17-1,2,4-1) X3, X4, X8, X11, X13, X16
RBFNN2 (16-1,2,4-1) X1, X9, X10, X11, X12, X13, X14
https://doi.org/10.1371/journal.pone.0227188.t002
Typology of patients with HIV-HCV infection to be treated with antivirals
PLOS ONE | https://doi.org/10.1371/journal.pone.0227188 January 10, 2020 7 / 14
The ROC curves for the three methods proposed are shown in Fig 1. The ROC curve pro-
vides a graphical display of true positives (TPR) and false positives (FPR) on the x− and y− axes,
respectively, where TPR is equivalent to sensitivity, and FPR is equal to 1 − specificity for vary-
ing cut-off points of test probability values. Although the performance of all the models was
competitive, it can be seen that the RBFNN provided the best results.
Furthermore, it could be thought that the application of a preprocessing technique to
reduce the dimensionality of the input variables would be of interest. However, it would make
the models deal with two additional disadvantages: a important lost of interpretability, since
the new input variables are combinations of the original ones, and a possible lost of perfor-
mance, due to the need of more robust and accurate information. In this sense, Principal Com-
ponents Analysis (PCA) [44] was run, concluding that 90% of the variance was explained by
using 12 variables, which is greater than the number of independent variables used by all the
models shown in Table 2. In this way, the RBFNN was run following the same experimental
design but considering this set of principal components as input variables. The average
Fig 1. ROC curve for the three models proposed.
https://doi.org/10.1371/journal.pone.0227188.g001
Typology of patients with HIV-HCV infection to be treated with antivirals
PLOS ONE | https://doi.org/10.1371/journal.pone.0227188 January 10, 2020 8 / 14
results of the 30 runs are 0.752 ± 0.007 in terms of CCR, 0.550 ± 0.026 in terms of MS and
0.767 ± 0.008 in terms of AUC, which are worse than the results obtained by all the models
with the original datasets. Furthermore, regarding the best model, it achieved the following
values: 0.750, 0.537 and 0.782 for CCR, MS and AUC, respectively. These are also worse than
the results obtained by the best models with the original dataset.
To consider the statistical significance of differences between means (CCR, MS, AUC and
#conn) for each ANN topology (SUNN, PUNN and RBFNN), the non-parametric Kolmogo-
rov-Smirnov (K-S) test for normality was used with α = 0.05, to evaluate whether CCR, MS,
AUC and #conn followed a normal distribution. Remember that all ANN models were run 30
times with different seeds. As can be seen from the results in Table 3, a normal distribution
can be assumed because the critical levels, p-values, were greater than 0.05 in most cases. One-
way ANOVA was used to determine the best methodology (in terms of CCR, MS, AUC and
#conn). The results of the ANOVA analysis showed that the effect of the methodology was sta-
tistically significant at a significance level of 5% (see the first row of Table 4). This test deter-
mined that there were significant differences between the results found by the different
methods, and multiple comparison tests were then carried out on the CCR, MS, AUC and
#conn values to rank the different methods. The Levene test [45] was used to evaluate equality
of variances, followed by the Tukey test [46], since the variances were equal (for all CCR, MS,
AUC and #conn), to rank the different methods.
As can be concluded from Table 4, RBFNN obtained statistically significant results for both
CCR and #conn, although for MS, the results were worse than those obtained with the other
models. The best model in terms of MS was SUNN. Finally, with respect to the AUC, there
were no significant differences, although the best results were obtained by RBFNN.
Table 3. P-values of the Kolmogorov-Smirnov test applied to the generalisation set for CCR, MS, AUC and #conn.
Variable PUNN SUNN RBFNN
CCR 0.138 0.200 0.003
MS 0.034 0.002 < 0.001
AUC 0.200 < 0.001 0.028
#conn 0.029 0.007 0.023
https://doi.org/10.1371/journal.pone.0227188.t003
Table 4. P-values of Snedecor’s F ANOVA I test ordered means for the multiple comparison Tukey test when con-
sidering CCR, MS, AUC and #conn for the models obtained.
CCR � MS �
F (p-values) < 0.001 < 0.001
Ranking of averages μPUNN� μRBFNN: p = 0.218 μPUNN� μSUNN: p = 0.368
μSUNN< μRBFNN: p< 0.001 μRBFNN� μPUNN: p = 0.022
μSUNN< μPUNN: p< 0.001 μRBFNN � μSUNN: p< 0.001
AUC #conn �
F (p-values) 0.221 < 0.001
Ranking of averages No significant differences μPUNN< μSUNN: p< 0.001
μRBFNN < μSUNN: p< 0.001
μRBFNN< μPUNN: p< 0.001
(�) Significant differences were found for α = 0.05.
https://doi.org/10.1371/journal.pone.0227188.t004
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The equations for the different models are provided in S1 Table. Based on these equations,
it can be concluded that the RBFNN model was not particularly complex, using just eight con-
nections and six independent variables, achieving a high performance. Table 5 shows the main
characteristics of this model, together with the variables considered, CCR, MS, AUC and the
confusion matrices (CM) on both the training and generalisation sets.
The table shows a reasonable CCR in the generalisation set, taking into account the small
number of independent variables. The MS indicates that the sensitivity for each class is good
enough, bearing in mind the imbalance between them. The AUC shows that our model has
good discriminatory power between patients in the treated and untreated classes. The confu-
sion matrices show the distribution of errors and the number of correctly classified patterns.
The Precision-Recall metric (PR) was calculated for this best model. The precision-recall
metric is a useful measure of success of prediction when the classes are very imbalanced. A
high AUC represents both high precision and high recall. In this case, PR was 0.766. The preci-
sion-recall curve is also shown in Fig 2 for evaluating the trade-off between precision and recall
for different thresholds.
Discussion
Three main points can be outlined for the best model:
1. The output function of the RBFNN model is a linear combination of radial basis functions
(see Table 5 and S1 Table) with a positive coefficient of 8.957, which means that the higher
the value of the basis function, the greater the probability of being treated.
2. The importance of the independent variable X4 (“Recent PWID”) is worthy of mention.
When this variable is left out of the model (see Table 2), accuracy decreases from 0.767 to
0.514, the minimum sensitivity decreases from 0.550 to 0.000, meaning that the model is
not a good classifier of any of the patterns belonging to the minority set (untreated patients)
and the AUC curve decreases from 0.802 to 0.573. Inclusion of this variable should there-
fore be mandatory because of its importance.
3. The parsimony of the model, in other words, the small number of independent variables,
is what makes it especially attractive: it is not necessary to obtain further information from
the patient, it reduces the time needed to obtain the same prediction accuracy, and it mini-
mises the likelihood of incurring in information errors.
Table 5. Main characteristics of the RBFNN model.
Variables X3: OST PWID
X4: recent PWID
X8: Naïve to therapy
X11: Liver fibrosis (1, 2, 3, 4)
X13: Age
X16: Genotype 3
Training Generalisation
CCR 0.757 0.767
MS 0.522 0.550
AUC 0.801 0.802
CM 1270 177
357 389
 !
440 65
109 133
 !
https://doi.org/10.1371/journal.pone.0227188.t005
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Conclusion
Application of a machine-learning methodology enabled us to identify variables associated
with lower uptake of HCV treatment. The variable “Recent PWID” was identified as the main
limiting factor related to the absence of treatment uptake, even when the prioritisation criteria
were met. This is a critical variable in the sense that absence of treatment uptake in this popula-
tion would involve a significant risk of HCV dissemination and the appearance of outbreaks.
A recent HIV and HCV outbreak associated with injection-drug use of oxymorphone in the
United States is a clear example of the importance of this point [47]. Recent PWIDs should
therefore be reconsidered as a priority population for implementation of HCV treatment in
order to minimise the risk of community-acquired HCV infection and maximise the impact of
therapy, leading to the objective of eliminating HCV in the future. The use of radial basis func-
tions neural networks, very simple models with regards to the number of patient characteris-
tics to be considered by the classifier, might be a useful tool for drawing up or modifying
strategic plans when tackling different diseases and, more specifically in the present case, for
Fig 2. Precision-Recall curve for the best model obtained.
https://doi.org/10.1371/journal.pone.0227188.g002
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maximising the impact of therapy. Indeed, Intelligent Network DisRuption Analysis (INDRA)
has been employed as a targeted strategy for the efficient interruption of hepatitis C transmis-
sion among PWIDs [48]. In our opinion, its use in clinical decision making in infectious
diseases should be expanded with a view to optimising recommendations for treatment and
prevention strategies.
Supporting information
S1 Table. Best models obtained for the different methodologies.
(PDF)
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